WuXi Biologics & Adagene partner to generate new antibody therapeutics
Category: #health  By Dhananjay Punekar  Date: 2018-03-09
  • share
  • Twitter
  • Google Plus
  • Facebook
  • LinkedIn

WuXi Biologics & Adagene partner to generate new antibody therapeutics

WuXi Biologics, an open-access biologics technology platform firm offering end-to-end services for exploring, developing, and manufacturing biologics, has declared a partnership with Adagene. This collaboration with the Chinese antibody discovery & engineering firm is apparently targeted at creating new antibody therapeutics.

Reportedly, Adagene’s association with WuXi Biologics will help the firm supply the products for clinical tests under the U.S. FDA’s Investigational New Drug program. Post the approval for marketing, these products would be liable to be shipped across the U.S. and China.

The co-founder and Chief Executive of Adagene Corporation, Dr. Peter Luo, has stated that its partnership with WuXi Biologics will help the firm to focus on the key functional areas such as discovering of new antibody therapeutics on difficult antigens. He believes that the process development & production competencies of WuXi will support Adagene’s focus on introducing new products in the healthcare market.

Industry analysts seem to be rather optimistic about this collaboration and view it as one of the best initiatives for introducing world-class life-saving biologics across the China pharmaceuticals market.  A key official of WuXi has stated that the high-quality biologics tool of the firm will help Adagene in creating new antibody therapeutics.

Reportedly, such partnerships will not only promote the expansion of the biopharmaceutical sector, but will encourage new drug innovation, which will help in curing chronic ailments of the patients. WuXi Biologics’ prominent end-to-end solutions will help Adagene to manufacture therapeutic drugs with improved biophysical characteristics.

With the growing competition witnessed across the healthcare & pharmaceutical industry, such alliances are likely to become commonplace, making medicines rather cost-effective & easily available, claim authentic sources. Indeed, analysts state that this strategic business decision will facilitate Adagene Incorporation’s next wave of innovative product development and its launch across clinics & hospitals across the globe.



About Author

Dhananjay Punekar

Email: dhananjay.p@news.marketsizeforecasters.com   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...

Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes
Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes
By Dhananjay Punekar

Kallyope Inc., a platform biotech company, and Novo Nordisk A/S, a Denmark based healthcare firm, have declared that they have both signed an option agreement for jointly carrying out research programs to discover new ...

FDA grants supplemental ANDA approval for Glenmark’s Monroe unit
FDA grants supplemental ANDA approval for Glenmark’s Monroe unit
By Dhananjay Punekar

Glenmark Pharmaceuticals, a pharma firm based in Mumbai, has received a green signal from U.S. FDA for its drug manufactured at Monroe at North Carolina facility. Incidentally, the approval has been granted for the pro...